Rivaroxaban: A Comprehensive Product Introduction
Rivaroxaban (CAS 366789-02-8) is a well – known and highly effective anticoagulant medication. It has revolutionized the field of thromboprophylaxis and the treatment of various thromboembolic disorders. In this article, we will delve deep into the properties, uses, applications in different fields, and the preparation methods of Rivaroxaban.
Properties of Rivaroxaban
Rivaroxaban is a small – molecule, direct factor Xa inhibitor. Its chemical name is 5 – Chloro – N – ({(5S) – 2 – oxo – 3 – [4 – (3 – oxomorpholin – 4 – yl)phenyl] – 1,3 – oxazolidin – 5 – yl}methyl)thiophene – 2 – carboxamide. It has a molecular formula of C₁₉H₁₈ClN₃O₅S and a molecular weight of 435.88 g/mol.
Physically, Rivaroxaban appears as a white to slightly yellowish powder. It is sparingly soluble in water, but soluble in organic solvents such as dimethyl sulfoxide (DMSO) and methanol. This solubility profile is important for its formulation into different dosage forms, such as tablets.
The stability of Rivaroxaban is an important consideration. It is stable under normal storage conditions (20 – 25°C, 60% relative humidity). However, it should be protected from light and moisture to prevent degradation.
Uses of Rivaroxaban
Prevention of Stroke in Atrial Fibrillation
Atrial fibrillation (AF) is a common cardiac arrhythmia that significantly increases the risk of stroke. Rivaroxaban has been shown to be highly effective in reducing the risk of stroke and systemic embolism in patients with non – valvular atrial fibrillation. It works by inhibiting factor Xa, which is a key enzyme in the coagulation cascade. By blocking factor Xa, Rivaroxaban reduces the formation of thrombin and subsequent fibrin clot formation, thus preventing the development of blood clots that can lead to stroke.
Prevention of Venous Thromboembolism (VTE)
Venous thromboembolism, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major health concern, especially in patients undergoing major orthopedic surgery (such as hip or knee replacement) or those who are immobilized for a long time. Rivaroxaban is used for the prevention of VTE in these high – risk patients. In patients undergoing hip or knee replacement surgery, it is typically started a few hours after surgery and continued for a specific period (usually 35 days for hip replacement and 12 days for knee replacement) to prevent the formation of blood clots in the veins of the lower extremities.
Treatment of Acute DVT and PE
For patients with acute DVT or PE, Rivaroxaban can be used as an alternative to traditional anticoagulant therapies such as warfarin. It has a more predictable anticoagulant effect, does not require frequent monitoring of the international normalized ratio (INR), and has a lower risk of major bleeding in some cases. The treatment regimen usually involves an initial higher – dose period followed by a lower – dose maintenance phase.
Applications in Different Fields
Medical Field
In the medical field, Rivaroxaban is a cornerstone in the management of thromboembolic disorders. It has been widely adopted in hospitals, clinics, and long – term care facilities. Physicians prescribe Rivaroxaban based on the patient’s risk factors, medical history, and the type of thromboembolic condition. It has also been included in many clinical practice guidelines, such as those from the American College of Chest Physicians (ACCP) and the European Society of Cardiology (ESC).
Pharmaceutical Research
Rivaroxaban serves as an important model compound in pharmaceutical research. Scientists are constantly studying its mechanism of action, pharmacokinetics, and pharmacodynamics to develop better – targeted anticoagulant drugs. Research is also being conducted to explore its potential use in other diseases where abnormal blood clotting is involved, such as cancer – associated thrombosis.
Clinical Trials
Many clinical trials are ongoing to evaluate the safety and efficacy of Rivaroxaban in different patient populations and disease states. These trials aim to expand the indications for Rivaroxaban and to compare it with other anticoagulant medications. For example, some trials are investigating its use in patients with end – stage renal disease, where the pharmacokinetics of Rivaroxaban may be different due to impaired renal function.
Preparation Methods of Rivaroxaban
The synthesis of Rivaroxaban involves multiple steps. One of the common synthetic routes starts with the preparation of key intermediates. The first step usually involves the synthesis of 4 – (3 – oxomorpholin – 4 – yl)aniline. This can be achieved by reacting 4 – fluoroaniline with morpholine – 3 – one in the presence of a base such as potassium carbonate.
The next step is the formation of the oxazolidinone ring. This is typically accomplished by reacting the intermediate obtained from the previous step with a suitable chloroacetyl derivative under specific reaction conditions. After that, the thiophene – 2 – carboxamide group is introduced. This is done by reacting the intermediate with thiophene – 2 – carbonyl chloride in the presence of a base to form the final product, Rivaroxaban.
During the synthesis process, strict control of reaction conditions such as temperature, reaction time, and the purity of starting materials is crucial to ensure high – yield and high – quality product. Purification steps, such as recrystallization and chromatography, are also necessary to obtain Rivaroxaban with the required purity for pharmaceutical use.
Send InquiryReferences
- PubMed – National Library of Medicine. This is a great resource for finding scientific articles related to Rivaroxaban and its applications in medicine.
- European Medicines Agency (EMA). Their website provides information on the approval, safety, and efficacy of Rivaroxaban in the European market.
- U.S. Food and Drug Administration (FDA). The FDA website contains details about the regulatory status and labeling of Rivaroxaban in the United States.